A review of myocardial ischaemia/reperfusion injury: Pathophysiology, experimental models, biomarkers, genetics and pharmacological treatment

Basit Öğe Kaydı
dc.authoridParlakpınar, Hakan/0000-0001-9497-3468
dc.authoridGunata, Mehmet/0000-0001-6905-4259
dc.authoridParlakpinar, Hakan/0000-0001-9497-3468
dc.authorwosidParlakpınar, Hakan/T-6517-2018
dc.authorwosidGunata, Mehmet/AAW-2738-2021
dc.authorwosidParlakpinar, Hakan/V-6637-2019
dc.contributor.authorGunata, Mehmet
dc.contributor.authorParlakpinar, Hakan
dc.date.accessioned2024-08-04T20:48:54Z
dc.date.available2024-08-04T20:48:54Z
dc.date.issued2021
dc.departmentİnönü Üniversitesien_US
dc.description.abstractCardiovascular diseases are known to be the most fatal diseases worldwide. Ischaemia/reperfusion (I/R) injury is at the centre of the pathology of the most common cardiovascular diseases. According to the World Health Organization estimates, ischaemic heart disease is the leading global cause of death, causing more than 9 million deaths in 2016. After cardiovascular events, thrombolysis, percutaneous transluminal coronary angioplasty or coronary bypass surgery are applied as treatment. However, after restoring coronary blood flow, myocardial I/R injury may occur. It is known that this damage occurs due to many pathophysiological mechanisms, especially increasing reactive oxygen types. Besides causing cardiomyocyte death through multiple mechanisms, it may be an important reason for affecting other cell types such as platelets, fibroblasts, endothelial and smooth muscle cells and immune cells. Also, polymorphonuclear leukocytes are associated with myocardial I/R damage during reperfusion. This damage may be insufficient in patients with co-morbidity, as it is demonstrated that it can be prevented by various endogenous antioxidant systems. In this context, the resulting data suggest that optimal cardioprotection may require a combination of additional or synergistic multi-target treatments. In this review, we discussed the pathophysiology, experimental models, biomarkers, treatment and its relationship with genetics in myocardial I/R injury. Significance of the study This review summarized current information on myocardial ischaemia/reperfusion injury (pathophysiology, experimental models, biomarkers, genetics and pharmacological therapy) for researchers and reveals guiding data for researchers, especially in the field of cardiovascular system and pharmacology.en_US
dc.identifier.doi10.1002/cbf.3587
dc.identifier.endpage217en_US
dc.identifier.issn0263-6484
dc.identifier.issn1099-0844
dc.identifier.issue2en_US
dc.identifier.pmid32892450en_US
dc.identifier.scopus2-s2.0-85090238312en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage190en_US
dc.identifier.urihttps://doi.org/10.1002/cbf.3587
dc.identifier.urihttps://hdl.handle.net/11616/99518
dc.identifier.volume39en_US
dc.identifier.wosWOS:000566271200001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofCell Biochemistry and Functionen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectacute myocardial infarctionen_US
dc.subjectexperimental modelsen_US
dc.subjectischaemiaen_US
dc.subjectreperfusion injuryen_US
dc.subjectoxidative stressen_US
dc.subjectpharmacological treatmenten_US
dc.titleA review of myocardial ischaemia/reperfusion injury: Pathophysiology, experimental models, biomarkers, genetics and pharmacological treatmenten_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu